Dec 9 2021
Immune checkpoint blockade (ICB) utilizing antibodies that block PD-1, PD-L1, and CTLA-4 has changed cancer patient care and started a new era, with long-term durable disease control in a subset of patients across multiple cancers. However, most patients do not respond to ICB therapy, and many who initially respond eventually develop recurrent and progressive disease. Our laboratory seeks to understand why this approach is active in some patients but ineffective in others, why some patients develop resistance to therapy, and how to overcome these barriers to ICB and generate effective systemic antitumor immunity. We will present examples of rationally designed combination therapies based on the changes in the immune system, systemically in the tumor microenvironment. These studies have been paralleled both in murine models and clinical settings. We hope these studies provide a framework for future early pre-clinical and clinical studies.
December 9, 2021
- Timing of the immune interventions is key.
- Targets must be present during the intervention.
- Immune precision approaches should be developed and guide the rational design of future clinical trials.
Dr. Taha Merghoub
Attending Biologist, Human Oncology & Pathogenesis Program Co-director, Ludwig Collaborative & Swim Across America Laboratory, Memorial Sloan Kettering Professor of Immunology Research in Medicine, Weill Cornell Medical College Member Researcher
Parker Institute for Cancer Immunotherapy
Dr. Merghoub directs the Ludwig Collaborative Laboratory and the Swim Across America Laboratory at Memorial Sloan Kettering (MSK). I am a member researcher of the Parker Institute for Cancer Immunotherapy at MSK. I also lead the biorepository for the Melanoma Service at MSK. My research project investigates the means for developing immune-based therapies to treat cancer. In addition, some of my work aims to study the pathogenesis and treatment of melanoma as a model system and is directed in part at developing tools to study melanoma, lung cancer, and immune responses in multiple cancers. My projects are heavily collaborative across different disciplines at MSK.